Stress Urinary incontinence Epidemiology Forecast
Key Highlights
- In the US, approximately 13 million individuals are directly affected by urinary incontinence. The prevalence is 50% or greater among residents of nursing facilities and rises to more than 75% among long-term (>100 days) residents.
- Stress urinary incontinence is the most common type of urinary leakage disorder, with a higher and increasing prevalence reported in women compared to men.
- In young adults, SUI is reported in 20–30% of women, while reaching its peak between 45 and 59 years of age with a prevalence of around 30–50%.
DelveInsight’s “Stress Urinary Incontinence (SUI)” report delivers an in-depth understanding of SUI, and historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2021-2034
Stress Urinary Incontinence (SUI) Understanding
Stress Urinary Incontinence (SUI) Overview
SUI can occur when the pelvic tissues and muscles that support the bladder and urethra weaken and sink around the bladder neck (where the bladder and urethra intersect) during physical activity. Even the weakened sphincter muscle cannot stop the flow of urine under normal circumstances and with increased abdominal pressure. The weakness can occur from pregnancy, childbirth, aging, or previous pelvic surgery. Other risk factors for SUI include chronic cough, obesity, and smoking.
Stress Urinary Incontinence (SUI) Diagnosis
Urine samples to detect infections, blood traces, or other abnormalities, brief neurological examination to identify, urinalysis, cystoscopy, pelvic nerve problems, urinary stress test, and bladder function test are some of the common diagnostic methods.
Further details related to diagnosis will be provided in the report…
Learn how the therapeutic market will evolve and grow in the coming years: Stress Urinary Incontinence Market
Stress Urinary Incontinence (SUI) Epidemiology
The Stress Urinary Incontinence (SUI) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of urinary incontinence, total diagnosed prevalent cases of urinary incontinence, type-specific diagnosed prevalent cases of urinary incontinence, gender-specific diagnosed prevalent cases of SUI, age-specific diagnosed prevalent cases of SUI, and total treated cases of SUI in the 7MM covering the US, EU4 (Germany, France, Italy, Spain) and the UK, and Japan from 2021 to 2034.
- It has been estimated that almost 62% of women experience some degree of urinary incontinence. Of these, 37.5% have stress urinary incontinence, and another 31% report the mixed type. This condition is prevalent in older females living in nursing homes, with up to 77% affected.
- Approximately 24% to 45% of women reported urinary incontinence. Among women aged 20 to 39, 7% to 37% experience some degree of incontinence. In women older than 60, approximately 9% to 39% reported urinary incontinence daily. An increased risk of urinary incontinence is associated with pregnancy, childbirth, diabetes, and increased body mass index.
- In Europe, the prevalence of stress urinary incontinence was estimated at ~14.5% among individuals aged 30 to 60.
- The prevalence of stress urinary incontinence in women increases with age (>70 years), menopause, obesity (body mass index at least 25 and especially >40), and the number of vaginal births.
Stress Urinary Incontinence (SUI) Report Insights
Stress Urinary Incontinence (SUI) Report Insights
- Patient Population
- Country-wise Epidemiology Distribution
Stress Urinary Incontinence (SUI) Report Key Strengths
- Ten Years Forecast
- 7MM Coverage
- SUI Epidemiology Segmentation
FAQs
- What are the disease risks, burdens, and unmet needs of Stress Urinary Incontinence? What will be the growth opportunities across the 7MM concerning the patient population with Stress Urinary Incontinence?
- What is the historical and forecasted Stress Urinary Incontinence patient pool in the US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Epidemiology Methodology
5 SUI Epidemiology Overview at a Glance
5.1 Patient Share (%) Distribution by Country of SUI in 2021
5.2 Patient Share (%) Distribution by Country of SUI in 2034
6 Disease Background and Overview
6.1 Introduction
6.2 Types of Urinary Incontinence
6.3 Signs and Symptoms
6.4 Causes
6.5 Diagnosis
6.6 Differential Diagnosis
6.8 Diagnosis Algorithm
6.9 Diagnostic Guidelines
7 Epidemiology and Patient Population of SUI in the 7MM
7.1 Key Findings
7.2 Assumptions and Rationales
7.3 Total Diagnosed Prevalent Cases of SUI in the 7MM
7.4 The United States
7.4.1 Total Prevalent Cases of Urinary Incontinence in the United States
7.4.2 Total Diagnosed Prevalent Cases of Urinary Incontinence in the United States
7.4.3 Gender-specific Diagnosed Prevalent Cases of SUI in the United States
7.4.4 Age-specific Diagnosed Prevalent Cases of SUI in the United States
7.4.5 Total Treated Cases of SUI in the United States
7.5 EU4 and the UK
7.5.1 Total Prevalent Cases of Urinary Incontinence in EU4 and the UK
7.5.2 Total Diagnosed Prevalent Cases of Urinary Incontinence in EU4 and the UK
7.5.3 Gender-specific Diagnosed Prevalent Cases of SUI in EU4 and the UK
7.5.4 Age-specific Diagnosed Prevalent Cases of SUI in EU4 and the UK
7.5.5 Total Treated Cases of SUI in EU4 and the UK
7.6 Japan
7.6.1 Total Prevalent Cases of Urinary Incontinence in Japan
7.6.2 Total Diagnosed Prevalent Cases of Urinary Incontinence in Japan
7.6.3 Gender-specific Diagnosed Prevalent Cases of SUI in Japan
7.6.4 Age-specific Diagnosed Prevalent Cases of SUI in Japan
7.6.5 Total Treated Cases of SUI in Japan
8 Appendix
8.1 Bibliography
8.2 Report Methodology
9 DelveInsight Capabilities
10 Disclaimer
11 About DelveInsight
List of Tables:
List of Tables
Table 1: Stress Urinary incontinence Epidemiology in 7MM (2021-2034)
Table 2: Stress Urinary incontinence Diagnosed and Treatable Cases in 7MM (2021-2034)
Table 3: Stress Urinary incontinence Epidemiology in the United States (2021-2034)
Table 4: Stress Urinary incontinence Diagnosed and Treatable Cases in the United States (2021-2034)
Table 5: Stress Urinary incontinence Epidemiology in Germany (2021-2034)
Table 6: Stress Urinary incontinence Diagnosed and Treatable Cases in Germany (2021-2034)
Table 7: Stress Urinary incontinence Epidemiology in France (2021-2034)
Table 8: Stress Urinary incontinence Diagnosed and Treatable Cases in France (2021-2034)
Table 9: Stress Urinary incontinence Epidemiology in Italy (2021-2034)
Table 10: Stress Urinary incontinence Diagnosed and Treatable Cases in Italy (2021-2034)
Table 11: Stress Urinary incontinence Epidemiology in Spain (2021-2034)
Table 12: Stress Urinary incontinence Diagnosed and Treatable Cases in Spain (2021-2034)
Table 13: Stress Urinary incontinence Epidemiology in the United Kingdom (2021-2034)
Table 14: Stress Urinary incontinence Diagnosed and Treatable Cases in the United Kingdom (2021-2034)
Table 15: Stress Urinary incontinence Epidemiology in Japan (2021-2034)
Table 16: Stress Urinary incontinence Diagnosed and Treatable Cases in Japan (2021-2034)
List of Figures:
List of Figures
Figure 1 Stress Urinary incontinence Epidemiology in 7MM (2021-2034)
Figure 2 Stress Urinary incontinence Diagnosed and Treatable Cases in 7MM (2021-2034)
Figure 3 Stress Urinary incontinence Epidemiology in the United States (2021-2034)
Figure 4 Stress Urinary incontinence Diagnosed and Treatable Cases in the United States (2021-2034)
Figure 5 Stress Urinary incontinence Epidemiology in Germany (2021-2034)
Figure 6 Stress Urinary incontinence Diagnosed and Treatable Cases in Germany (2021-2034)
Figure 7 Stress Urinary incontinence Epidemiology in France (2021-2034)
Figure 8 Stress Urinary incontinence Diagnosed and Treatable Cases in France (2021-2034)
Figure 9 Stress Urinary incontinence Epidemiology in Italy (2021-2034)
Figure 10 Stress Urinary incontinence Diagnosed and Treatable Cases in Italy (2021-2034)
Figure 11 Stress Urinary incontinence Epidemiology in Spain (2021-2034)
Figure 12 Stress Urinary incontinence Diagnosed and Treatable Cases in Spain (2021-2034)
Figure 13 Stress Urinary incontinence Epidemiology in the United Kingdom (2021-2034)
Figure 14 Stress Urinary incontinence Diagnosed and Treatable Cases in the United Kingdom (2021-2034)
Figure 15 Stress Urinary incontinence Epidemiology in Japan (2021-2034)
Figure 16 Stress Urinary incontinence Diagnosed and Treatable Cases in Japan (2021-2034)
*The table of contents is not exhaustive; will be provided in the final report